The World Health Organisation (WHO) announced its plans to set up a technology transfer hub in South Africa aimed at enhancing local production of COVID-19 vaccines across the African continent. This move is a concerted strategy to address the stark dearth of vaccines in the region.
The initiative focuses on fostering collaboration among regional vaccine manufacturers to expedite knowledge transfer, with the ultimate goal of hedging against future pandemics.
This plan comes amid the continued struggle in African nations to source a sufficient number of COVID-19 vaccine doses, thus inhibiting a comprehensive immunization drive. Therefore, by catalyzing regional vaccine production, the WHO aims to amplify the African continent’s ability to safeguard against the existing pandemic and future outbreaks.
The tech transfer hub will function as a partnership between the WHO, Afrigen Biologics, a South African pharmaceutical firm, several global pharmaceutical companies, and an alliance of universities. These multiple stakeholder engagements will cultivate an ecosystem conducive to knowledge sharing, resulting in the accelerated production of efficacious vaccines.
Significantly, this initiative marks the maiden acquisition of mRNA (messenger ribonucleic acid) technology in Africa, an innovation that powers the Pfizer and Moderna vaccines. mRNA technology essentially instructs cells to produce a protein, triggering an immune response, and resulting in the generation of antibodies against the COVID-19 virus. This technology has revolutionized vaccine development and provides a robust foundation for managing emerging and re-emerging diseases.
This move by the WHO is a hallmark step in bolstering Africa’s self-reliance in immunization and signals an essential advancement in access to life-saving technology. By ensuring the ongoing exchange of expert knowledge and enabling the proliferation of leading-edge technology in Africa, the WHO’s tech transfer hub promises a holistic and robust response to pandemics.
